These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 12627925

  • 1. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa.
    Tam VH, Louie A, Lomaestro BM, Drusano GL.
    Pharmacotherapy; 2003 Mar; 23(3):291-5. PubMed ID: 12627925
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF, Bulitta J, Lipman J, Kirkpatrick CM.
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion.
    Burgess DS, Hastings RW, Hardin TC.
    Clin Ther; 2000 Jan; 22(1):66-75. PubMed ID: 10688391
    [Abstract] [Full Text] [Related]

  • 4. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
    Goff DA, Nicolau DP.
    Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
    Ludwig E, Konkoly-Thege M, Kuti JL, Nicolau DP.
    Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.
    Cheatham SC, Shea KM, Healy DP, Humphrey ML, Fleming MR, Wack MF, Smith DW, Sowinski KM, Kays MB.
    Int J Antimicrob Agents; 2011 Jan; 37(1):46-50. PubMed ID: 21074370
    [Abstract] [Full Text] [Related]

  • 12. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?
    Kim A, Sutherland CA, Kuti JL, Nicolau DP.
    Pharmacotherapy; 2007 Nov; 27(11):1490-7. PubMed ID: 17963458
    [Abstract] [Full Text] [Related]

  • 13. Comparison of five beta-lactam antibiotics against common nosocomial pathogens using the time above MIC at different creatinine clearances.
    Kays MB.
    Pharmacotherapy; 1999 Dec; 19(12):1392-9. PubMed ID: 10600088
    [Abstract] [Full Text] [Related]

  • 14. Evaluating outcomes of alternative dosing strategies for cefepime: a qualitative systematic review.
    Burgess SV, Mabasa VH, Chow I, Ensom MH.
    Ann Pharmacother; 2015 Mar; 49(3):311-22. PubMed ID: 25575975
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.
    Kim A, Kuti JL, Nicolau DP.
    Clin Ther; 2009 Nov; 31(11):2765-78. PubMed ID: 20110018
    [Abstract] [Full Text] [Related]

  • 19. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004.
    DeRyke CA, Kuti JL, Nicolau DP.
    Pharmacotherapy; 2007 Mar; 27(3):333-42. PubMed ID: 17316145
    [Abstract] [Full Text] [Related]

  • 20. Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens.
    Rhodes NJ, Grove ME, Kiel PJ, O'Donnell JN, Whited LK, Rose DT, Jones DR, Scheetz MH.
    Int J Antimicrob Agents; 2017 Sep; 50(3):482-486. PubMed ID: 28668694
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.